Earnings
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
Israel-based Teva Pharmaceutical’s second-quarter financial report led off with a dramatic 18 percent drop in quarterly revenue compared to the same period the year before. The company reported second-quarter sales of $4.7 billion.
Cambridge, Massachusetts-based Epizyme emphasized its efforts to move tazemetostat back into clinical trials in its second-quarter financial report.
Regeneron Pharmaceuticals reported its second-quarter financial results, citing quarterly total revenues of $1.608 billion, up 9 percent from the same quarter in 2017 of $1.470 billion.
As its acquisition by Takeda Pharmaceutical edges closer and closer, Shire reported a solid second-quarter.
For its second-quarter financial report, Paris-based Sanofi reported a decrease in net sales for the quarter of 5.7 percent, down to 8.176 billion euros. Sanofi’s diabetes and cardiovascular franchises have struggled in the U.S.
Pfizer reported its second-quarter financials, with adjusted earnings per share coming in at $0.81, exceeding the consensus forecast of $0.74, up 20.9 percent from the same period in 2017.
Investors have been skeptical about AbbVie lately, particularly after last week’s second-quarter financial report. That doesn’t make all that much sense, given that the company reported net revenues of $8.278 billion for the quarter.
Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by Eliquis (apixaban) and Opdivo (nivolumab).
Despite what has been described as a series of missteps in the last year, Celgene’s second-quarter financial report was promising.
PRESS RELEASES